Get started
Author

Michael F. Crutchlow

Observed names: M.F. Crutchlow, MICHAEL CRUTCHLOW, Michael Crutchlow, Michael F Crutchlow
ORCID: 0000-0002-9686-9047
Observed ORCID: 0000-0002-9686-9047
OpenAlex ID: A5048833820
The diabetes gene Pdx1 regulates the transcriptional network of pancreatic endocrine progenitor cells in mice
2009 · Jennifer M. Oliver-Krasinski, Margaret T. Kasner, et al. · Journal of Clinical Investigation · 176
PDF
Calcineurin Signaling Regulates Human Islet β-Cell Survival
2010 · Scott A. Soleimanpour, Michael F. Crutchlow, et al. · Journal of Biological Chemistry · 145
PDF
Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus
2005 · Diva D. De León, Michael F. Crutchlow, et al. · The International Journal of Biochemistry & Cell Biology · 94
Transplant-Associated Hyperglycemia
2007 · Michael F. Crutchlow, Roy D. Bloom · Clinical Journal of the American Society of Nephrology · 88
New-Onset Diabetes Mellitus in the Kidney Recipient
2008 · Roy D. Bloom, Michael F. Crutchlow · Clinical Journal of the American Society of Nephrology · 57
Identification of transcriptional targets during pancreatic growth after partial pancreatectomy and exendin-4 treatment
2006 · Diva D. De León, Cyrus Farzad, et al. · Physiological Genomics · 47
Clinical Evaluation of MK ‐2640: An Insulin Analog With Glucose‐Responsive Properties
2018 · Alexander W. Krug, Sandra A.G. Visser, et al. · Clinical Pharmacology & Therapeutics · 42
Exendin-4 Normalizes Islet Vascularity in Intrauterine Growth Restricted Rats: Potential Role of VEGF
2009 · J Nina Ham, Michael F Crutchlow, et al. · Pediatric Research · 39
PDF
Transplant-associated hyperglycemia
2007 · Roy D. Bloom, Michael F. Crutchlow · Transplantation Reviews · 30
Overall and subgroup prevalence of non-alcoholic fatty liver disease and prevalence of advanced fibrosis in the United States: An updated national estimate in National Health and Nutrition Examination Survey (NHANES) 2011-2018
2023 · Tongtong Wang, Yuzhi Xi, et al. · Annals of Hepatology · 22
Single‐dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK ‐1293 insulin glargine and originator insulin glargine ( L antus) in subjects with type 1 diabetes and healthy subjects
2017 · Michael F. Crutchlow, John S. Palcza, et al. · Diabetes Obesity and Metabolism · 20
PDF
Direct Comparison of Radioimmunoassay and LC–MS/MS for PK Assessment of Insulin Glargine in Clinical Development
2014 · Yang Xu, Marita Prohn, et al. · Bioanalysis · 18
Clinical Trial: A Phase 2b Study to Evaluate the Efficacy and Safety of MK‐3655 in Individuals With Pre‐Cirrhotic MASH
2025 · Annaswamy Raji, Ira Gantz, et al. · Alimentary Pharmacology & Therapeutics · 16
Validation of Steady-State Insulin Sensitivity Indices in Chronic Kidney Disease
2007 · Michael F. Crutchlow, Bruce Robinson, et al. · Diabetes Care · 15
PDF
Efficacy and safety of MK‐1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open‐label clinical trial
2018 · Priscilla A. Hollander, Wendy L. Carofano, et al. · Diabetes Obesity and Metabolism · 13
Double‐blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT‐M study
2019 · Juan P. Frias, Zachary Zimmer, et al. · Diabetes Obesity and Metabolism · 12
PDF
Exendin-4 Does Not Promote Beta-Cell Proliferation or Survival During the Early Post-Islet Transplant Period in Mice
2008 · M.F. Crutchlow, M. Yu, et al. · Transplantation Proceedings · 11
Dose distribution and up‐titration patterns of metformin monotherapy in patients with type 2 diabetes
2019 · Kristy Iglay, Baanie Sawhney, et al. · Endocrinology Diabetes & Metabolism · 10
PDF
Efficacy and safety of MK‐1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open‐label clinical trial
2018 · Philip D. Home, Raymond L. H. Lam, et al. · Diabetes Obesity and Metabolism · 9
Combined GPR40 and GPR119 full agonism with K‐757 and K‐833 results in robust glucose lowering and modest weight loss in overweight/obese subjects with T2DM
2025 · Michael Crutchlow, Jiajun Liu, et al. · Diabetes Obesity and Metabolism · 3
Combined agonism of nutrient receptors GPR40 and GPR119 with K‐757 and K‐833 results in weight loss and blood pressure reductions in obese subjects without type 2 diabetes mellitus
2025 · Michael Crutchlow, Jiajun Liu, et al. · Diabetes Obesity and Metabolism · 2
Maximizing endogenous β-cell regeneration
2007 · Michael F Crutchlow, Doris A Stoffers · Current Opinion in Organ Transplantation · 2
A Mechanism Based Population Pharmacokinetic- Pharmacodynamic Model for Epoetin Alfa and Darbepoetin Alfa in Chronic Kidney Disease Patients
2010 · Amit Garg, Anis A. Khan, et al. · 1
TRPM 8 Antagonism with Elismetrep: A Novel Approach for Treating Migraine (S37.001)
2026 · Brett Lauring, Peter Goadsby, et al. · Neurology
Author response for "Combined agonism of nutrient receptors GPR40 and GPR119 with K‐757 and K‐833 results in weight loss and blood pressure reductions in obese subjects without type 2 diabetes mellitus "
2025 · Michael Crutchlow, Jiajun Liu, et al.
Works count: 33
Citation count: 872
H-index: 14
I10-index: 18
Year
Topic
Type